Loading...
XNAS
ELUT
Market cap15mUSD
Jul 09, Last price  
0.97USD
1D
2.32%
1Q
-13.98%
IPO
-31.72%
Name

Aziyo Biologics Inc

Chart & Performance

D1W1MN
XNAS:ELUT chart
P/E
0.29
P/S
1.28
EPS
3.30
Div Yield, %
Shrs. gr., 5y
35.05%
Rev. gr., 5y
-22.04%
Revenues
12m
-49.57%
39,038,00042,901,00042,682,00047,390,00023,849,00024,745,00024,375,00012,293,000
Net income
53m
P
-11,566,000-11,939,000-21,825,000-24,832,000-32,897,000-37,656,000-53,949,00053,380,000
CFO
-45m
L+97.78%
-5,125,000-7,225,000-13,626,000-15,446,000-21,434,000-21,761,000-22,657,000-44,810,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aziyo Biologics, Inc. (AZYO) operates as a regenerative medicine firm, concentrating its efforts on developing advanced medical products. Their primary applications target three key areas: implantable electronic devices and cardiovascular care, orthopedic and spinal repair, and the reconstruction of soft tissues. The company's product portfolio includes CanGaroo, an innovative envelope that incorporates antibiotics, specifically engineered to lower the risk of infection following the surgical implantation of an electronic device. Aziyo also provides a suite of cardiovascular solutions. ProxiCor serves as an intracardiac patch or pledget for repairing heart tissues, while Tyke is designed for neonates and infants to mend pericardial structures. Additionally, VasCure offers a versatile patching material for the repair or reconstruction of peripheral blood vessels, encompassing critical arteries like the carotid, renal, iliac, femoral, and tibial, serving cardiovascular, vascular, and general surgeons. For orthopedic procedures, Aziyo offers human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V. These products are formulated to protect and preserve the body's natural bone cells. In the realm of soft tissue repair, they feature SimpliDerm, a pre-hydrated human acellular dermal matrix (HADM) developed for the repair or replacement of damaged or insufficient skin and related integumental tissues. Beyond its proprietary product line, Aziyo Biologics extends contract manufacturing services, producing various items for other corporate clients. The company distributes its products to hospitals and other healthcare facilities through a multi-faceted sales approach, utilizing its dedicated direct sales force, strategic commercial partners, and independent sales agents. Founded in 2015, Aziyo Biologics, Inc. maintains its headquarters in Silver Spring, Maryland.
IPO date
Oct 08, 2020
Employees
151
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT